Application of Patient-Specific iPSCs for Modelling and Treatment of X-Linked Cardiomyopathies

Area of Science:

• Cardiovascular Medicine
• Genetics
• Regenerative Medicine

Background:

• Inherited cardiomyopathies are a leading cause of heart failure, with over 70 genes implicated.
• X-linked cardiomyopathies present modeling challenges due to limited cell and animal models.
• X-chromosome inactivation mosaicism leads to heterogeneous disease phenotypes in heterozygous females.

Purpose of the Study:

• To review current strategies for using induced pluripotent stem cell (iPSC)-based models to study X-linked cardiomyopathies.
• To highlight the potential of iPSC technology for in vitro modeling and drug screening.
• To address the limitations of iPSC-derived cardiomyocyte platforms.

Main Methods:

• Utilizing patient-derived iPSC lines to create in vitro models of X-linked cardiomyopathy.
• Employing advancements in iPSC procedures to isolate cells with varying X-chromosome inactivation patterns.
• Generating isogenic disease and control cell lines for comparative studies.
• Demonstrating preliminary data on isogenic iPSC lines from a female patient with heterozygous Danon disease for drug screening.

Main Results:

• iPSC technology facilitates the in vitro modeling of X-linked cardiomyopathies.
• Isogenic iPSC lines enable the study of heterogeneous disease presentations in females.
• Preliminary data suggests potential for iPSC-based drug screening in conditions like Danon disease.

Conclusions:

• iPSC-based models offer a powerful platform for understanding and potentially treating X-linked cardiomyopathies.
• Further research is needed to overcome the limitations of iPSC-derived cardiomyocyte models.
• This technology holds promise for personalized medicine approaches in genetic heart diseases.